Jon Ellis, CEO, Trenchant BioSystems | Onyx Live | ISCT Dublin 2026
Fewer than 10% of eligible CAR-T patients ever get treated. Trenchant BioSystems CEO Jon Ellis says the bottleneck is no longer the science – it's manufacturing.
Sean Werner, CTO, BioLife Solutions | Onyx Live | ISCT Dublin 2026
Most cell therapies arrive at the patient frozen – and BioLife Solutions CTO Sean Werner says the field still treats what happens after manufacturing as an afterthought.
Augustin de Bettignies, Chief Business Officer, MPC Therapeutics | Onyx Live | ISCT Dublin 2026
Most of cell therapy fixates on the cell's target. MPC Therapeutics' Augustin de Bettignies says its metabolism — what it burns during manufacturing — matters just as much.
Stephen Sullivan, Founder & Managing Director, Lindville Bio | Onyx Live | ISCT Dublin 2026
Most cell therapies don't fail at the finish line – they fail at the start, says iPSC consultant Stephen Sullivan. Why early decisions decide late outcomes.
Jeff Galecke, Managing Partner, i5 BioPartners | Onyx Live | ISCT Dublin 2026
The cell and gene therapy tools companies that scale aren't always the ones with the best technology, says i5 BioPartners' Jeff Galecke – they're the ones that can tell a clear story.
Sven Kili, Partner, Saisei Ventures | Onyx Live | Cell & Gene Meeting on the Med 2026
Great science isn't enough to get funded, says investor Sven Kili – only great medicines are. Inside the CGT funding squeeze, and what specialist VCs actually screen for.
Bruce Levine, Co-inventor of Kymriah, University of Pennsylvania | Onyx Live | ISCT Dublin 2026
Nine years after Kymriah, the first ever CAR-T cell therapy, was approved, around 10,000 patients have been treated. Inside CAR-T’s next decade with co-inventor Bruce Levine.
Miguel Forte, President, ISCT | Onyx Live | ISCT Dublin 2026
Cell and gene therapy is having its golden age, says ISCT President Miguel Forte – and is still in adolescence. Inside the field's reshaping priorities.
Marion Hitchcock, Managing Director, Gene & Cell Therapies Incubator Berlin | Onyx Live | Cell & Gene Meeting on the Med 2026
In cell and gene therapy, the science is rarely the bottleneck – making it at scale is. Inside the Bayer–Charité incubator betting on Berlin to fix that.